LSEG’s Marcus Stuttard speaks to Dr Gordon Sanghera, CEO and Co-Founder of Oxford Nanopore Technologies, about the UK-based biotech company’s route to market and the benefits that has bought them, from credibility amongst global investors to attracting top talent.

As the discussion uncovers, what really sets the business apart is their extraordinary clinical research and scalable technology solutions. Dr Sanghera also explains how Oxford Nanopore has created a revolutionary DNA & RNA sequencing device which will bring huge benefits to humanity in early disease and cancer diagnosis.  The very definition of an inspiring company.